3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Lymphoid
1
Conditions
Multiple Myeloma
130
Recurrence
34
Lymphoma, Follicular
28
Lymphoma, Large B-Cell, Diffuse
27
Lymphoma, Non-Hodgkin
23
Neoplasms
13
Lymphoma
13
Lymphoma, Mantle-Cell
11
Lymphoma, B-Cell, Marginal Zone
11
Leukemia, Lymphocytic, Chronic, B-Cell
11
Hematologic Diseases
5
Neoplasms, Plasma Cell
4
Myelodysplastic Syndromes
4
Lymphoma, B-Cell
4
Hematologic Neoplasms
4
Neoplasm Metastasis
3
Melanoma
3
Leukemia, Myeloid, Acute
3
Pyloric Stenosis, Hypertrophic
2
Prostatic Neoplasms
2
Paraproteinemias
2
Ovarian Neoplasms
2
Lymphoproliferative Disorders
2
Lymphoma, T-Cell, Peripheral
2
Leukemia-Lymphoma, Adult T-Cell
2
Leukemia, B-Cell
2
Leukemia
2
Immunoproliferative Disorders
2
Hodgkin Disease
2
Carcinoma, Non-Small-Cell Lung
2
Interventions
Rituximab
8
dacetuzumab
5
blinatumomab
5
ibrutinib
3
Cyclophosphamide
3
tetulomab tetraxetan lu-177
2
ponatinib
2
cobomarsen
2
acalabrutinib
2
Vincristine
2
Prednisone
2
Lutetium
2
Ifosfamide
2
Everolimus
2
Etoposide
2
Doxorubicin
2
Carboplatin
2
venetoclax
1
sepantronium
1
pomalidomide
1
obinutuzumab
1
fludarabine
1
ficlatuzumab
1
enzalutamide
1
durvalumab
1
denileukin diftitox
1
cirmtuzumab
1
amonafide
1
Vorinostat
1
Tinzaparin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Lymphatic Diseases
×
Lenalidomide
×
Clear all
NCT02733042
2023-11-18
FUSION NHL 001
Celgene
Phase 1/2
Completed
106 enrolled
48 charts